TRIM21 and interstitial lung disease: This risk ILD substantially increased to 38-fold for patients who had both anti-ARS and anti-Ro-52 antibodies, compared to individuals lacking either of these antibodies (adjusted OR = 38.39, 95% CI: 8.83–167.00; p < 0.001).